Kurv Yield Premium Strategy Tesla (TSLA) ETFTSLP
TSLP
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
6.09% less ownership
Funds ownership: 6.09% [Q2] → 0% (-6.09%) [Q3]
50% less funds holding
Funds holding: 2 [Q2] → 1 (-1) [Q3]
100% less capital invested
Capital invested by funds: $207K [Q2] → $48 (-$207K) [Q3]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for TSLP.
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Tesla Stock Hits All-Time High: ETFs to Ride the Momentum
Tesla shares hit an all-time high. Several analysts raised price targets.
Neutral
Business Wire
1 month ago
Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Suite ETFs into the Kurv ETF Trust. This transition marks a significant milestone in the company's growth and operational evolution. The Yield Premium Suite includes: Kurv Yield Premium Strategy Amazon (AMZN) ETF Kurv Yield Premium Strategy Apple (AAPL) ETF Kurv Yield Premium Strategy Google (GOOGL).
Neutral
Business Wire
4 months ago
Kurv Announces Special Distributions
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Announces Special Distributions.
Neutral
Business Wire
7 months ago
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Charts implemented using Lightweight Charts™